Enterprise Value
30.25M
Cash
5.843M
Avg Qtr Burn
-10.1M
Short % of Float
4.87%
Insider Ownership
2.82%
Institutional Own.
20.36%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SLS-005 (trehalose) Details Spinocerebellar Ataxia | Phase 2/3 Data readout | |
SLS-005 (trehalose) Details Amyotrophic lateral sclerosis | Phase 2/3 Data readout | |
SLS-005 (trehalose) Details Sanfilippo Syndrome | Phase 2/3 Initiation | |
SLS-002 (intranasal ketamine) Details Major depressive disorder, Acute Suicidal Ideation and Behavior | Phase 2 Update | |
GFH009 Details Relapsed/refractory acute myeloid leukemia, Acute myeloid leukemia | Phase 1 Data readout | |
SLS-005 (trehalose) Details Oculopharyngeal Muscular Dystrophy | Failed Discontinued | |
SLS-006 Details Parkinson's disease | Failed Discontinued |